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Objective: To explore the vision related health quality-of-life before and after the injection of anti-
angiogenic drug in vitreous cavity to patients with wet-AMD.
Methods: The 2000 edition of Visual Functioning Questionnaire-25 issued by National Eye Institute is
applied, and the VRQL evaluation is conducted on the initial diagnosed patients with wet-AMD before
and after the injection of ranibizumab drugs in vitreous cavity.
Results: Among the wet-AMD patients, patients with better distance visual acuity before the intravitreal
injection get lower VFQ-25 score; while after the vitreous cavity injection, the VFQ-25 questionnaire
score is related to the explanation and nursing of doctors and nurses towards patients, the better the
nursing, the higher the score.
Conclusion: Before vitreous cavity injection, the degree of distance visual acuity is an important factor
affecting VRQL of wet-AMD patients, in addition, the explanation and nursing of doctors and nurses
toward patients during pre-operation, intra-operation and post-operation of intravitreal injection are
also the import factors affecting VROL.
© 2015 Shanxi Medical Periodical Press. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Age-related macular degeneration (AMD) is one of the major
causes of blindness in the elderly. AMD usually occurs in people
over the age of 45, with both eyes got the disease at the same time
or successively, the vision damage is progressive, which can seri-
ously affecting the quality of life of older person.1,2 Along with so-
cial progress and improvement of living standards, people are
requiring increasingly high demand of quality life, therefore, the
demand for understanding of early AMD and effective treatment
are becoming urgent. Clinically, AMD is divided into two types: the
ﬁrst one is atrophic AMD, also known as dry AMD, which isScience Fund Project (No.
n of Shanghai Natural fund
al Periodical Press.
g, and Xiao-Xia Chen, equally
Production and hosting by Elsevcharacterized by a progressive retinal pigment epithelium (RPE)
atrophy, leading to degeneration of photoreceptor cells, and
causing central vision loss; the second one is exudative AMD, also
known as wet AMD or senile discoid macular degeneration, which
is characterized by the formation of abnormal choroidal neo-
vascularization under RPE, causing varying degrees of edema,
exudation, hemorrhage and scar change in macular region of eyes
ground. In June 2006, the FDA approved that Lucentis drug was
available for the treatment of intravitreal injection for wet-AMD
patients. Lucentis drug is a recombinant humanized monoclonal
antibody fragment (Fab), targeted inhibition of vascular endothelial
growth factor A (VEGF-A), thus inhibiting the combination of VEGF-
A with its receptors VEGFR-1 and VEGFR -2, preventing prolifera-
tion of vascular endothelial cell and angiogenesis of new vessels.3e5
In Dec, 2011, it was approved by SFDA for clinical, with very sig-
niﬁcant clinical treatment effect, but the surgery has certain risks
and affecting factors. The explanation to patients and nursing
during pre-operation, intra-operation and post-operation also play
a very important role to the surgery success, our experience is re-
ported as follows.ier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Subconjunctival hemorrhage after intravitreal injection in the left eye.
D.-D. Wang et al. / Chinese Nursing Research 2 (2015) 27e30282. Subjects and methods
2.1. Survey subjects
It is a retrospective analysis regarding the basic situation of our
ﬁrst diagnosed 20 cases patients suffering fromwet-AMD in single
eye from 2012 to 2013. In the 20 cases, there are 11 males account
for 55%, and 9 females account for 45%, aged from 41 to 68 years
old, with an average age of 57.68, 3 cases with the vision from 0.01
to 0.05 account for 15%, 15 cases with the vision from 0.05 to 0.3
accounts for 75%, 2 cases with the vision from 0.3 to 0.5 accounts
for 10%, their eyes have no other anterior segment and posterior
segment diseases (such as glaucoma, diabetic retinopathy, retinal
detachment, etc.) and systemic disease, patients have a certain
understanding ability, who have also ﬁlled out the VFQ-25 ques-
tionnaire carefully before and after vitreous cavity injection
surgery.
2.2. Methods
2.2.1. Eyes examination
During the initial diagnosis, Snellen international standard
distant vision chart with lamp house is applied tomeasure patients'
best corrected visual acuity of both eyes, at the same time, a non-
contact tonometer (NIDEK, NT-2000) is used to measure intraoc-
ular pressure, and a slit lamp to exam anterior segment, the stan-
dard 90-degree pre-focusing mirror to exam eye ground, in
addition with 3D-OCT (Topcon, 3D OCT-1000) and HRA2 fundus
ﬂuorescence angiography for clear diagnosis, in the end, 16 cases of
patients are diagnosed with typical wet-AMD, and 4 cases are
diagnosed with latent wet-AMD.
2.2.2. Fill out the VFQ-25 questionnaire
After the eyes examination, all of the subjects have to ﬁll out
VFQ-25 questionnaire, and measure the VRQLscore. VFQ-25 ques-
tionnaire consists of three parts, namely, (1) the overall health
condition and vision: including the degree of self-satisfaction to-
ward systemic disease and the binocular vision correction; (2) ac-
tivities: including reading newspapers and street signs, ﬁnding
items, outdoor activities and driving; (3) the consequences of vision
problem: including limited mobility, unable to do what wanted,
and the psychological feeling brought about because of vision, the
higher the score of VFQ-25 questionnaire, the worse the VRQL.
2.2.3. Method of intravitreal injection of Lucentis
Currently, the most common and most effective way to cure
wet-AMD is intravitreal injection of anti-vascular endothelial
growth factor (anti-VEGF) drugs. After the deﬁnite diagnosis for
above patients, Lucentis drug is injected in vitreous cavity, the
operation requires very strict sterilization operating room. After at
least 3 times of ocular surface anesthesia, the eyes around is ster-
ilized and ready with towel, sterile eye speculum is used, and the
roots of eyelashes are disinfected, and then disinfect the conjunc-
tival sac once again with PVP. Extract 0.05 ml drug with 1 ml sterile
syringe, replace the needle with a special needle for 30G intra-
vitreal injection, empty the air to the needle tip, the needle should
be injected at 3.5e4.0 mm backward of limbus, align with the eye
center, and perpendicular to the sclera in vitreous cavity, but to pay
attention that the entry point on bulbar conjunctiva and scleral
surface are better not to point the same site, so as to reduce the
possibility of postoperative infection of the eye, then slowly push
the 0.05 ml injection into the vitreous cavity, before that 0.05 ml
aqueous liquid should be extracted from patients who have done
cataract surgery and implanted with intraocular lens to prevent the
Lucentis injection permeates through the aqueous due tointraocular lens implantation, after injection, press the needle eye
for 3e5 min, lay over the TobraDex eye ointment and bind up with
sterile gauze. For patients needs both eyes treatment, a new in-
jection is required for the other eye, in addition, the sterile towel,
syringe, gloves, surgical drape, speculum, and injection needles are
all needed to be changed before injected to the other eye.
2.3. Nursing before and after intravitreal injection
First of all, ask the patients to instill antibiotic drop by them-
selves three days before the injection, 4 times a day, with the
purpose to eliminate the infection in conjunctiva of the eye and
circumocular; second, as the price of Lucentis is quite expensive
(9800 Yuan/injection), therefore, before the injection, it requires
detail explanation of it, that is the disease can be controlled, but the
vision is not necessarily be improved; third, circumocular and
systemic condition (such as intraocular pressure, blood pressure,
blood sugar, liver and kidney function, ECG) are required to be
controlled in the normal range, and without drug allergies; fourth,
anti-inﬂammatory eye drops should be used for 7 to 10 days
consecutively, no bathwithin 24 h, and no rubbing eyes hardwithin
one week, in particular, the coal mining, high-altitude operation,
long-time driving and other hazardous work can't be performed
within one week. Fifth, inform the patients that if there is red eyes
pain, subconjunctival hemorrhage (Fig. 1), vision blurs more, eyes
swelling or general discomfort, please come to the hospital for
treatment timely to avoid serious complications that may occur.
The nursing we talked about after injection is also consistent with
the report of Li Yong and other scholars. During the follow-up after
one year, the 20 patients' eyes BCVA, IOP, 3D-OCT and fundus
angiography should be checked again and the patient will be asked
to ﬁll out a detailed VFQ-25 questionnaire.
3. Results
Scores of the 20 wet-AMD patients in the initial ﬁlling out of
VFQ-25 questionnaire are as follows: the therapeutic visual acuity
is divided into three ranges, respectively, 0.01e0.05,0.05e0.3 and
0.3e0.5, in each range, the higher the BCVA for contralateral non-
treated eye, the lower the score of VFQ-25 questionnaire, that is
the patient has higher VRQL. Patients in the range of 0.05 to 0.3
have the lowest average VFQ-25 questionnaire score, that is, they
have higher VRQL, which is corresponding to the highest BCVA
average value for non-treated eye; Patients in the range of 0.01 to
0.05 have the highest average VFQ-25 questionnaire score, that is,
they have lower VRQL, which is corresponding to the lowest BCVA
average value for non-treated eye; Patients within the range of 0.3
to 0.5 have the average VFQ-25 score, which is also match with the
fact the BCVA average value for non-treated eye is in between.
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patients have improved their visual acuity by more than 3 lines
accounts with better and cured fundus photography (Fig. 2a, b), 5
cases of patients have no signiﬁcant visual acuity improvement and
accounting for 25.0%, 3 cases of patients even have decreased visual
acuity compared with the baseline value due to various complica-
tions and accounting for 15.0%, the reasons for diminution of vision
in these cases including vitreous hemorrhage, atrophic scarring in
macular lesions (Fig. 3a, b), etc. Our results are consistent with
Mitchell report.5 During the one year follow-up after injection of
Lucentis drug, the improvement of care vision and the nursing as
well as explanation of doctors toward patients have a signiﬁcantly
inﬂuence on the ﬁnal score of VFQ-25.Fig. 3. a. Color fundus and OCT picture pre-intravitreal injection with wet-AMD
accompanied by retinal hemorrhage and edema of the macula. b. Color fundus and
OCT picture post-intravitreal injection after 3 months; retinal hemorrhage and edema
disappeared but obviously a scar formed in the macula.4. Discussion
Wet-AMD is more rapidly progressed compared with dry-AMD,
it causes the oozing, bleeding, swelling and scarring of the macula,
and seriously affecting the patients' central vision. Clinically, for
patients with wet AMD, all of the different treatment methods can
get a certain effect, but each treatment has risks, for example,
although the photodynamic therapy (PDT) can effectively control
the disease progression, it also effects the restoration of visual
function,6,7 which requires actively and effectively communication
and explanation with patients prior to treatment; Another treat-
ment method is intravitreal injection of anti-VEGF drug, this
treatment can improve vision while no form of obvious scars in the
macula,8 thereby it has an important role of restoring visual func-
tion and improving visual quality, however, this method also has its
disadvantage, that is approximately 0.05% of the patients occurs
with endophthalmitis,9 about approximately 0.01% of the patients
will have stroke or cerebrovascular accident.10,11 From our research
result, 3 patients end up having poor therapeutic effect, the reasons
are as follows: complications occur after a variety of drug injection,
such as vitreous hemorrhage, lesion obvious scarring, as well as
latent wet-AMD patients have a poor sensitivity toward anti-VEGF
drugs.12
This experiment studies the main factors affecting VRQL before
and after the injection of intravitreal Lucentis drug, prior to theFig. 2. a. Color Fundus and OCT picture pre-intravitreal injection with wet-AMD;
hemorrhage and edema in the macula were noted. b. Color fundus and OCT picture
post-intravitreal injection of wet-AMD after 1month; hemorrhage and edema in the
macula area almost disappeared.treatment, patients rely on the good eye during daily life, thereby,
the better the distant vision, the higher the VRQL, which is
consistent with the research result from Zou Haidong and Immo-
nen, et al.2,13e15 After the treatment of intravitreal injection of drug
on the eye with poor vision, the subjective experience of patients
can signiﬁcantly affect VRQL, as the patients are looking forward to
the efﬁcacy, and there will be mentally and ﬁnancially burden, so
the work of doctors, including nursing, health education and
explanationwill also affect the patients' VRQL. This phenomenon is
also consistent with the results of Keeffe's observation.16
5. Conclusion
Prior to the treatment, for wet-AMD patients, the distant vision
of the good eye is crucial to the vision function related quality of
life; while after the intravitreal injection of drug, the main factors
affecting the vision function related quality of life including the
accuracy of diagnosis and the skills of injection, as well as the
explanation and nursing, and the recovery of the poor eye. There-
fore, after the injection of anti-VEGF drug, the improvement of vi-
sual function and quality of life are depending on the doctor's skills,
nurses' caring as well as the understanding and cooperation of
patients.
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